Biological consequences and physical complaints were compared for donors randomly assigned either to blood stem cell (BSC) or bone marrow (BM) donation. In the period 1994-1999, 61 consecutive donors were included. The BSC donors were given G-CSF 10 g/kg s.c., daily during 5 days before the first leukapheresis. Nineteen donors had one leukapheresis, 10 required two and one donor needed three leukaphereses in order to reach the target cell number of 2 ؋ 10 6 CD34 + cells/kg bw of the recipient. A median platelet nadir of 102 ؋ 10 9 /l was reached shortly after the last leukapheresis. Three weeks post harvest, 17 of 30 BSC donors had a mild leukopenia. Six had a leukopenia lasting more than a year before returning to normal values. Both groups were monitored prospectively through a standardised questionnaire completed by the donors. BSC donation was significantly less burdensome than BM donation and was preferred by the donors. The short-term risks of BSC mobilisation and harvest seem negligible. The potential long-term effects of G-CSF are unresolved and the donors must be followed closely. Bone Marrow Transplantation (2002) 29, 479-486.
This calls for cautious screening of candidates for the BSC method. 17 The long-term safety is not sufficiently documented. 30 Allogeneic BSC gives more rapid recovery of neutrophils and platelets and may shorten hospital stay. [5] [6] [7] [8] [9] [10] [11] Some authors speculate that the BSC graft may result in an enhanced graft-versus-leukaemia effect. [6] [7] [8] [9] [10] [11] [31] [32] [33] [34] [35] The choice of stem cell source, however, must also take into consideration the safety and complications for the donor. The present study focuses on blood tests, clinical chemistry, physical, psychological and social implications for donors of BSC or BM and is part of a randomised study of allogeneic transplantation with stem cells from blood or bone marrow at Rikshospitalet University Hospital, Oslo, initiated in June 1994. 9 
Subjects and methods

Donors
Consecutive pairs of patients and their HLA-identical or 1 A, B, or DR HLA antigen mismatched family donors were evaluated for inclusion in the study. The donors were between 15 and 62 years of age. From June 1994 until February 1999, 31 were randomised to BSC and 30 to BM harvest. The characteristics of all 61 donors randomised are summarised in Table 1 . Inclusion criteria were age above 15 years, good health and fit for general anaesthesia, bone marrow harvest or leukapheresis. Exclusion criteria were positive serology for hepatitis B or C, HIV or a history of previous malignant disease. Each donor went through a physical examination prior to inclusion. The following additional investigations were performed: complete blood cell count with WBC differential, Na, K, urea, creatinine, ASAT, ALAT, alkaline phosphatases, bilirubin, HB s Ag, serology of cytomegalovirus, herpes simplex, varicella zoster, HIV, HCV, HB c , toxoplasma and syphilis, morphological assessment of the bone marrow (to serve as control for later G-CSF treatment), chest X-ray, ECG and urine examination. All the donors were given the same information regarding the two harvest procedures in a neutral way prior to randomisation.
Study design
In donors randomised to BSC the following tests were performed on days 4 and 5 of growth factor treatment (and later if repeated leukaphereses were required): the yield of CD34 + progenitor cells, complete blood cell count and clinical chemistry. On day 28 a bone marrow aspirate was performed to examine the effects of G-CSF upon cell morphology and differentiation. Donors randomised to BM were monitored for haemoglobin the day after BM harvest and again 6 weeks later. The donors have been followed up for approximately 4.5 years so far.
Automated haematology analyses on fresh material from hospitalised donors or donors attending the outpatient clinic were routinely performed on a CellDyn 3500 (Abbott Laboratories, Abbott Park, IL, USA) haematology instrument. The follow-up analyses were taken by the donor's primary physician, sent by mail to the laboratory, and analysed on a Technicon H*3 (Technicon Bayer, Tarrytown, NY, USA) instrument within 48 h of blood sampling. CD34 + cells were enumerated according to the Nordic protocol. 36 All donors answered a questionnaire about their physical, psychological and social ability on day 0 (defined as the first day of growth factor treatment for the BSC group and the day of stem cell harvest for the BM group), and furthermore on days +1, +4, +7, +14, +28 and +90 after transplantation. Their physical and social limitations were assessed and the donors were asked to explain the nature of discomfort. The severity of the complaints was given a score from 1 to 4. Score 1 represented no change compared to the status before mobilising treatment or harvest, 2 mild changes, 3 moderate changes and 4 severe changes. Twice, and at least a year after harvest they were interviewed about their global experience as donors. They were also asked which method they would prefer if asked to repeat the donation.
The number of analgesic tablets, blood transfusions, requirement of central venous line, the number and the duration of leukaphereses, duration of hospitalisation, sick leave and the number of days with restricted activities were also recorded.
Written informed consent was obtained from all donors and recipients. The study was approved by The Regional Committee for Medical Research Ethics, Health Region II.
Harvest procedures
Donors randomised to undergo BSC collection were treated with filgrastim (r-metHuG-CSF) (Neupogen, Hoffmann-La Roche, Basel, Switzerland) at a dose of 10 g/kg/day s.c. for 5 consecutive days. Harvesting was performed by leukapheresis on the 5th day of treatment, initiated approximately 4 h after the last injection of G-CSF. Automated blood cell separators with either continuous flow (Cobe Spectra, Denver, CO, USA) or intermittent flow (Haemonetics, Braintree, MA, USA) were used. ACD was used as anticoagulant. Venous access was established by the antecubital veins. A minimum of 2 ϫ 10 6 CD34 + cells/kg/recipient weight was collected. If the first leukapheresis gave less than the required yield of CD34 + cells, the donor was given another injection of filgrastim the next morning and a second leukapheresis was performed 4 h later. The procedure was repeated a third time, if necessary.
Donors randomised to BM were harvested from both posterior iliac crests under general anaesthesia. Five thousand units of heparin were given intravenously per-operatively as antithrombotic prophylaxis. One unit of autologous erythrocytes was infused at the end of the harvest procedure. A minimum of 2 ϫ 10 8 nucleated cells/kg recipient weight was required for transplantation.
Statistical analysis
The comparisons of the results from the questionnaire for the two groups have been performed with t-tests. To accommodate multiple tests, the P values were Bonferroni corrected. To study physical, psychological and social abilities between the two groups repeated measurement models were used. The response variable was the sum of both physical and social complaints on days 0, +1, +4, +7, +14, +28 and +90. The two groups were used as between-subject factors. The questions were designed so that the value = 1 represented a pre-treatment value.
Some of the donors did not answer all the questions in the questionnaire. The questions were highly correlated with correlation coefficients ranging between 0.658 and 0.978. Therefore, rather than using imputation methods to fill in the missing values, the resulting score was computed as an average of the observed values.
A resulting sum score of 10 questions was merged to a mean discomfort score for both physical and social complaints. Non-parametric comparisons were applied between groups according to the Wilcoxon signed rank test.
The procedures in SPSS (SPSS, Chicago, IL, USA) were used to perform the statistical analysis.
Results
Short-term effects
Mean discomfort scores derived from the 10 questions are presented in Table 2 . There were significant differences in physical complaints between the two groups, but no apparent differences regarding the social complaints. Figure 1 shows the means of the sum scores for day +1 to 481 Table 2 Mean discomfort score expressing physical and social limitations from all days reported (days 0-90) The donors were asked if they had noticed any change in their physical or social ability whilst (1) running, (2) using stairs, (3) bending, carrying, lifting, (4) walking on level ground, (5) sitting, (6) consuming food/drink, (7) having social intercourse, (8) watching TV, (9) reading newspapers, (10) resting during night. day +90 for the two groups. The BSC donors experienced significantly less discomfort than the BM donors at day 0 and day +1 (P Ͻ 0.001). The repeated measurement model shows that for the BSC group the level of discomfort was significantly higher than the pre-treatment value until day +7 (P Ͻ 0.001). The BM group needed 14 days to return to the pre-treatment value. The median number of days spent in hospital was 0 (range 0-1) for BSC donors and 2 (range 1-9) for BM donors (P Ͻ 0.001). Sick leave in the BSC donors was significantly lower than in the BM group (P Ͻ 0.001) as shown in Figure 2 . The consumption of analgesics (paracetamol, sometimes combined with codein) was higher in the BSC group (P = 0.003) (Figure 3 ).
BSC donors
Thirty of 31 donors completed the questionnaire. They experienced physical and social limitations from the second day of G-CSF injection, reaching the maximum limitation at the day of leukapheresis. Their discomfort resolved com- Table  3 . G-CSF treatment could be completed in all donors. One donor did not feel any discomfort at all. During the leukapheresis, one-third of the donors experienced peribuccal and finger paresthesias attributed to hypocalcemia induced by ACD, requiring calcium administration. None of the donors needed central venous access or hospitalisation. In 19 donors sufficient material was obtained by one single leukapheresis. In 10 donors two leukaphereses were required. In one donor three leukaphereses were performed with a cumulative yield of only 1.8 ϫ 10 6 CD34 + cells/kg recipient weight, which proved sufficient when administered to the recipient. A donor who did not experience any Table 3 Complaints and signs
Low
adverse effects during the mobilising treatment with G-CSF reached a total number of only 0.9 ϫ 10 6 CD34 + cells/kg recipient weight after two leukaphereses. An additional BM harvest was therefore performed. A summary of the characteristics of the BSC collections is shown in Table 4 .
The blood counts in BSC donors before, 28 days and 1 year or more post harvest are given in Table 5 . The donors had a six-fold increase of leukocytes on days 4 and 5 of filgrastim treatment. Two days after discontinuation the value was more than halved. Twenty-eight days after the treatment started the median leukocyte count was back to pre-treatment value. Twelve donors had mild lymphopenia (lymphocyte count Ͻ1.5 ϫ 10 9 /l), eight of them normalised Table 4 Summary of BSC collection data shortly afterwards. Five donors had a mild neutropenia (granulocyte count Ͻ2 ϫ 10 9 /l), three of them normalised during the following 4 weeks. Platelet counts always dropped and the decrease was proportional to the number of leukaphereses. In 13 cases counts dropped below 100 ϫ 10 9 /l. In one donor a count of 49 ϫ 10 9 /l was recorded 2 days after the third leukapheresis. Bleeding did not occur and substitution with autologous platelets was not necessary. Bone marrow smears prepared 4 weeks after G-CSF treatment showed no morphological abnormalities. A transient increase of serum alkaline phosphatases, lactate dehydrogenases and uric acid was observed during mobilisation. The values were within the reference range by 3 weeks post harvest.
BM donors
Twenty-eight of 30 donors completed the questionnaire. The maximum score of discomfort was recorded on the day of bone marrow harvest followed by several days with physical and social limitations. Two donors ranged their limitation as mild, three as moderate and in 23 cases as severe. One donor developed transient bronchospasm at the end of the harvest procedure. General anaesthesia was used in all but one donor who preferred spinal anaesthesia. Infection or bleeding that required additional transfusions did not occur. Pain at the collection site, tiredness and consequently restricted activity were the most common complaints ( Table 3) .
The median haemoglobin level pre-harvest was 13.8 g/dl (range 11.6-16.7), dropping to 11.2 g/dl (range 7.4-13.3) 1 day after the harvest. One female donor had a significant anaemia post harvest (7.4 g/dl) and needed a 9 days hospital stay because of weakness and dizziness. Iron substitution was given to all the donors, and discontinued when the haemoglobin normalised as assessed by their general practitioner.
Long-term effects
The long-term surveillance of complaints in BSC donors has so far not detected any disorder that could be associated with G-CSF treatment or the harvest procedures. Until now BSC donors have been observed for a median of 53 months. The donors have no complaints. Two donors whose sibling recipient died within 5 months have reported feelings of guilt. The donor that was excluded from the study due to the need of both BSC and BM donation, died 26 months after the harvest procedures of pulmonary embolism, and further studies have not disclosed likely links to the G-CSF treatment. His blood counts 1 year post harvest were within normal range. A comparison between the pre-harvest values and counts a year or more after the G-CSF treatment are shown in Table 5 . Six donors had a transient leukopenia. In one donor with normal pre-harvest values, a neutrophil count of 0.8 ϫ 10 9 /l was recorded two years after the mobilising treatment, but normalised later (Figure 4) .
The BM donors did not report any complaints a year or more after the harvest with a median observation time of 54.5 months. A comparison between BSC and BM donors' Donation of SC from blood or bone marrow D Heldal et al 483 Table 5 Pre-harvest compared to post harvest blood counts in BSC donors blood counts 1 year or more post harvest did not show any difference.
All donors would donate again if asked. Twenty-six of the BSC donors would prefer the same method, while the answers among the BM donors were more diverse, as shown in Table 6 . The negative attitude to bone marrow harvest was linked to the side-effects of general anaesthesia, the inability to visit the recipient on the day of transplantation and the need for sick leave afterwards. Table 6 Preferences of method of stem cell collection if asked again
Same method 98% 33% Indifferent 2% 32% Alternative method 0 34%
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Discussion
Our study documents a striking difference in the total burden of complaints in the two groups of donors, favouring the BSC arm. The difference in duration of hospital stay and sick leave shows the same trend. These experiences obviously influence the preferences of the donors, as indicated by Switzer et al. 37 Surprisingly, we found that the BSC donors required more analgesics than the BM donors, probably due to the nature of discomfort and the fact that they were expected to go to work after having injected their daily doses of growth factor. The method used for informing donors may have influenced their expectations, with a possible impact on the post-procedure assessment. Nevertheless, our results are in conflict with the conclusion in another recently published randomised study on experiences of donors. Rowley et al 38 reported similar levels of physical discomfort regardless of the collection procedure used. However, they scored symptom burden differently by differentiating between physical and emotional experiences in contrast to the global parameters utilised in our study. Besides, they used a 50% higher dose of G-CSF than we did.
None of the BM donors experienced life-threatening complications or lasting discomfort. Earlier studies have shown a low incidence of complications. Some cardio-pulmonary problems, infectious complications, cerebrovascular episodes and transient neuropathies have been reported. [1] [2] [3] [4] Most of the life-threatening events are related to the use of general anaesthesia. The global experience of BM harvesting shows that for the vast majority of donors the procedure is acceptable. The question arises whether the BSC method is preferable for all donors.
As shown in earlier trials, the BSC donors experience a substantial increase in leukocytes. So far, there has been no confirmation of the possibly associated risk of ischemic events for individuals with vascular disease. 17 It has been suggested that the headache recorded during G-CSF treatment may be caused by increased viscosity of the blood or neutrophil infiltration in brain parenchyma. 39 Some authors, therefore, recommend a reduction of the cytokine dose if the WBC increases above 70 ϫ 10 9 /l. 17 In our study, only one male donor reached that level. He had headache but no other complaints. We believe that the clinical symptoms and the pre-mobilisation state of the donor are more relevant than setting an arbitrary upper limit.
Thrombogenic complications linked to G-CSF treatment may be of some concern. Two donors who developed a myocardial infarction and a cerebrovascular event, respectively, 17 and a patient with arterial thrombosis in association with G-CSF treatment and/or apheresis, have been reported. 28 Elevation in plasma of thrombogenic factors such as vWF Ag and FVIII 40 and increased platelet aggregation has also been reported. [41] [42] [43] In our study none of the donors experienced any of these complications. One donor who underwent coronary surgery 2 years before donation was given aspirin. We consider the risk for ischemic events as a relative contraindication for use of the BSC method in donors with history of atherothrombotic syndromes.
Leukapheresis leads to transient thrombocytopenia. The nadir is reached within 2 days after the last harvest. The number of aphereses necessary to collect the target number of CD34 + progenitor cells is inversely related to the magnitude of the platelet drop. The decrease in platelet number may also be due to inhibitory effects of G-CSF on platelet production. 26 However, the platelet count rapidly returns to normal values. 4, 21, [43] [44] [45] Some authors suggest re-infusion of autologous platelets if the platelet number declines below 80 ϫ 10 9 /l, which may occur among donors needing two or more aphereses. 4, [46] [47] [48] This may reduce the number of CD34 + progenitor cells in the apheresis product which is undesirable from the recipient's point of view. In our study neither autologous nor allogeneic platelet transfusions were produced or given despite transient platelet levels below 80 ϫ 10 9 /l. Bleeding complications were not observed. Autologous platelet transfusions in non-bleeding donors at a fixed platelet level seems more relevant to avoid legal liability than to alleviate medical needs.
Among our donors, 39% needed more than one apheresis to reach the target number of 2 × 10 6 CD34 + /kg recipient body weight and one donor required a supplementary bone marrow harvest. The question may be raised whether a higher dose or a fractionated dose of G-CSF could have reduced the number of leukapheresis procedures. Previous trials addressing this topic have so far not given clear-cut results. [49] [50] [51] [52] In addition, our study indicates that continuous flow is more efficient than intermittent flow separation (Table 4) .
Another factor of interest is the volume of blood processed. In our study a median of 3.5 estimated volumes of blood were exchanged at each apheresis (continuous flow). Usually the volume processed per apheresis represents 1.5 to three times the donor's estimated total blood volume. 53 Some authors have indicated that large volume leukapheresis (more than three times total blood volume) maximises the CD34 + cell yield. [54] [55] [56] Our results are not conclusive. In six BSC donors a mild leukopenia was observed later than 1 month post harvest. All had normal values pre-harvest and all had returned within the reference range at the latest follow-up. The explanation for this is unclear. None of the donors had any long-term discomfort 1 year or more after harvest, confirming previous reports. 24, 30, 53 However, it would be premature to conclude that the long-term safety of the BSC method is fully documented. The mild asymptomatic leukopenia observed in a limited number of cases is a matter of some concern. Another uncertainty not yet decided, is whether short-term treatment with G-CSF may injure the haematopoietic system in some sensitive individuals. So far, there are no data to support the notion that G-CSF treatment may promote haematological malignancies. 57 On the other hand, the question has been raised whether long-term immune functions have been sufficiently monitored in healthy donors to exclude the possibility that G-CSF treatment may influence the immune system. 58 Consequently, we recommend surveillance of BSC donors, with special attention to those with abnormal post-harvest blood values or unexpected symptoms.
In conclusion, the short-term safety of the two harvest procedures appears acceptable from a technical point of view. There are fewer complaints associated with the BSC method than with the BM method, and most donors would prefer the BSC method if asked again to donate. Still, we believe further experience should be collected before the BSC method is recommended as standard. In our centre BSC is first choice only for patients with high-risk leukaemia if other considerations do not decide the matter.
